Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed,
and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government
operating status and resumption of normal operations can be found at opm.gov.
A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
18 years old at time of consent
Diagnosed with a solid tumor that has progressed despite standard therapy or for which no standard effective or curative options exist or are suitable
EGFR-positive tumor expression
Adequate blood and organ function
Must agree to use contraception while on study and for 12 weeks after the last dose of IMGN289 as applicable
Must be willing and able to sign informed consent and follow the study schedule and other protocol requirements
Other anti-cancer treatment during the study
Symptomatic brain metastases
Other clinically significant disease as defined by the protocol
Chronic skin condition that requires prescribed oral or intravenous treatment
History of severe rash that required discontinuation of prior EGFR targeted therapy
Receiving therapeutic doses of warfarin or heparin for anti-coagulation